Jim Simons’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.2M | Buy |
1,665,078
+505,500
| +44% | +$9.78M | 0.06% | 426 |
|
|
2025
Q4 | $25M | Sell |
1,159,578
-1,490,600
| -56% | -$31.4M | 0.04% | 508 |
|
|
2025
Q3 | $51.1M | Buy |
2,650,178
+2,025,700
| +324% | +$36.1M | 0.07% | 343 |
|
|
2025
Q2 | $10.7M | Buy |
+624,478
| New | +$26.6M | 0.01% | 1025 |
|
|
2024
Q4 | – | Sell |
-230,478
| Closed | -$28.8M | – | 3901 |
|
|
2024
Q3 | $28.8M | Sell |
230,478
-121,522
| -35% | -$16.8M | 0.04% | 509 |
|
|
2024
Q2 | $55.6M | Sell |
352,000
-38,278
| -10% | -$4.92M | 0.09% | 254 |
|
|
2024
Q1 | $50.5M | Sell |
390,278
-172,700
| -31% | -$21.2M | 0.08% | 307 |
|
|
2023
Q4 | $54.3M | Sell |
562,978
-119,900
| -18% | -$11.5M | 0.08% | 280 |
|
|
2023
Q3 | $82.8M | Buy |
682,878
+40,800
| +6% | +$4.61M | 0.14% | 153 |
|
|
2023
Q2 | $73.5M | Sell |
642,078
-164,400
| -20% | -$21.2M | 0.11% | 214 |
|
|
2023
Q1 | $111M | Buy |
806,478
+87,600
| +12% | +$11.4M | 0.15% | 156 |
|
|
2022
Q4 | $93.2M | Sell |
718,878
-165,300
| -19% | -$19.2M | 0.13% | 165 |
|
|
2022
Q3 | $97.7M | Buy |
884,178
+490,900
| +125% | +$49.5M | 0.14% | 157 |
|
|
2022
Q2 | $29.5M | Buy |
393,278
+244,478
| +164% | +$18M | 0.03% | 550 |
|
|
2022
Q1 | $11.6M | Sell |
148,800
-86,778
| -37% | -$6.65M | 0.01% | 1029 |
|
|
2021
Q4 | $21.2M | Buy |
235,578
+227,078
| +2,672% | +$19.4M | 0.03% | 676 |
|
|
2021
Q3 | $786K | Sell |
8,500
-119,478
| -93% | -$9.2M | ﹤0.01% | 2676 |
|
|
2021
Q2 | $9.95M | Buy |
+127,978
| New | +$9.7M | 0.01% | 1171 |
|
|
2020
Q4 | – | Sell |
-156,578
| Closed | -$22M | – | 3703 |
|
|
2020
Q3 | $22M | Sell |
156,578
-299,900
| -66% | -$45.6M | 0.02% | 698 |
|
|
2020
Q2 | $73.2M | Buy |
456,478
+376,800
| +473% | +$51.3M | 0.06% | 336 |
|
|
2020
Q1 | $7.79M | Buy |
+79,678
| New | +$9.11M | 0.01% | 1312 |
|
|
2019
Q4 | – | Sell |
-348,078
| Closed | -$26.2M | – | 3731 |
|
|
2019
Q3 | $26.2M | Buy |
348,078
+255,200
| +275% | +$30.1M | 0.02% | 814 |
|
|
2019
Q2 | $14.1M | Buy |
+92,878
| New | +$11.3M | 0.01% | 1178 |
|
|
2018
Q4 | – | Sell |
-107,978
| Closed | -$17.4M | – | 3601 |
|
|
2018
Q3 | $17.4M | Sell |
107,978
-387,500
| -78% | -$53M | 0.02% | 1016 |
|
|
2018
Q2 | $65.5M | Buy |
495,478
+239,700
| +94% | +$22.6M | 0.07% | 326 |
|
|
2018
Q1 | $19M | Buy |
+255,778
| New | +$17.1M | 0.02% | 967 |
|
|
2017
Q2 | – | Sell |
-86,078
| Closed | -$2.55M | – | 3351 |
|
|
2017
Q1 | $2.55M | Buy |
86,078
+37,000
| +75% | +$1.15M | ﹤0.01% | 2106 |
|
|
2016
Q4 | $1.35M | Buy |
+49,078
| New | +$1.97M | ﹤0.01% | 2413 |
|
|
2016
Q1 | – | Sell |
-188,578
| Closed | -$7.28M | – | 3513 |
|
|
2015
Q4 | $7.28M | Sell |
188,578
-319,160
| -63% | -$10.3M | 0.02% | 1206 |
|
|
2015
Q3 | $16.3M | Buy |
507,738
+212,560
| +72% | +$7.21M | 0.04% | 605 |
|
|
2015
Q2 | $8.98M | Sell |
295,178
-101,361
| -26% | -$2.07M | 0.02% | 1038 |
|
|
2015
Q1 | $5.27M | Buy |
396,539
+232,261
| +141% | +$3.1M | 0.01% | 1331 |
|
|
2014
Q4 | $2.38M | Buy |
+164,278
| New | +$2.78M | 0.01% | 1708 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Jim Simons's SRPT Position: Q1 2026 in Review
Jim Simons increased its Sarepta Therapeutics (SRPT) stake by 44% in Q1 2026, buying an estimated $9.78M and bringing the position to 1,665,078 shares worth $36.2M. The position accounts for 0.06% of the portfolio, ranked #426.
Jim Simons first reported a position in SRPT in Q4 2014 and has held it in 33 quarters since. The position peaked at $111M in Q1 2023. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Jim Simons held 1,665,078 shares of Sarepta Therapeutics worth $36.2M as of Q1 2026.
- Jim Simons bought 505,500 Sarepta Therapeutics shares in Q1 2026, an estimated $9.78M.
- Sarepta Therapeutics made up 0.06% of Jim Simons's portfolio in Q1 2026, its #426 holding.
- Jim Simons first reported a position in Sarepta Therapeutics in Q4 2014 and has held it in 33 quarters since.
- Jim Simons's Sarepta Therapeutics position peaked at $111M in Q1 2023.
- 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.